RxDoctor Payments Data

Ranjan Duara, MD

Neurology · Miami Beach, FLNPI 1134159700

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,556 of the $10,800 with a category attached, or 70.0%. Novo Nordisk accounts for 78.4% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $9,437, more than ten times the $175 reported in 2019.

$10,800in general payments, 2019–2025

Across 109 payments — averaging $99.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$8K
  • Otsuka America Pharmaceutical, Inc.$730
  • Eisai Inc.$643
  • Lilly USA, LLC$338
  • Corium, LLC$130
  • Idorsia Pharmaceuticals US Inc$114
  • plus $376 from 7 others
$831,285in research payments, 2019–2025

Across 60 payments — averaging $13,855 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$644K
  • Eisai Inc.$102K
  • Novartis$83K
  • Merck$3K

What the payments were for

  • Consulting fees$7,55670%
  • Speaking & faculty fees$230%
  • Travel & lodging$6296%
  • Food & beverage$2,59124%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,800 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$74,210
Medicare patients
219
Services billed
405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Galantamine ErGalantamine Hbr372$44,636
Rivastigmine172$26,552
MyrbetriqMirabegron32$24,488
Memantine Hcl ErMemantine Hcl272$23,233
Memantine Hcl514$13,118
NamzaricMemantine Hcl/Donepezil Hcl11$12,572
Quetiapine Fumarate299$6,866
Sertraline Hcl502$6,270
Mirtazapine261$5,443
Donepezil Hcl334$3,731
Duloxetine Hcl88$3,542
Quetiapine Fumarate ErQuetiapine Fumarate53$3,155
Olanzapine72$3,136
Lamotrigine155$2,318
Bupropion XlBupropion Hcl90$2,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric$88$12,57211 claims
Lilly USA, LLCOlanzapine$338$3,13672 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami Beach

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →